Trials / Terminated
TerminatedNCT03306329
DNS-7801 vs. Placebo in Parkinson's Disease
A Phase 2a, Double-Blind, Placebo-Controlled Two-Part Study To Investigate the Safety and Efficacy of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Dart NeuroScience, LLC · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, two-part placebo-controlled parallel group outpatient treatment study that will utilize standard Parkinson's Disease measures to evaluate the effect of DNS-7801
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DNS-7801 (low-dose) | DNS-7801 (low-dose) tablets administered once daily. |
| DRUG | DNS-7801 (high dose) | DNS-7801 (high dose) tablets administered once daily. |
| DRUG | Placebo | Placebo tablets administered once daily |
Timeline
- Start date
- 2017-09-13
- Primary completion
- 2017-12-31
- Completion
- 2017-12-31
- First posted
- 2017-10-11
- Last updated
- 2018-02-01
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03306329. Inclusion in this directory is not an endorsement.